| Literature DB >> 33921891 |
Anello Marcello Poma1, Sarah Salehi Hammerstad2,3, Angelo Genoni4, Alessio Basolo5, Knut Dahl-Jorgensen2,6, Antonio Toniolo7.
Abstract
BACKGROUND: Hashimoto's thyroiditis and Graves' disease are autoimmune thyroid disorders (AITD) of unknown origin. Enterovirus (EV) infection of thyroid cells has been implicated as a possible initiator of cell damage and of organ-specific autoimmunity. We asked whether persistent infection of human epithelial cells with EV strains obtained from thyroid tissue of AITD patients could be associated with transcriptional changes capable of fostering immunopathology.Entities:
Keywords: CCL2; IL-18; autoimmunity; cytokine; interferon; pathogenesis; persistent infection; thyroiditis; virus
Year: 2021 PMID: 33921891 PMCID: PMC8073039 DOI: 10.3390/microorganisms9040876
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Clinical data of AITD cases selected for analysis of RNA transcripts. Out-of-range values are in bold.
| Group | Case No. | Classification | Sex | Age (Years) | TSH | FT4 | FT3 | TPO-Ab | Tg-Ab | TR-Ab |
|---|---|---|---|---|---|---|---|---|---|---|
| No evidence of thyroid autoimmunity | T15 | Ctrl | F | 62 | 0.63 | 13.5 | 7.5 | 34 | 19 | 0.09 |
| T16 | Ctrl | F | 55 | 0.91 | 17.3 | 6.2 | 34 | 19 | 0.09 | |
| T18 | Ctrl | F | 62 | 0.95 | 14.3 | 6.7 | 13 | 19 | 0.09 | |
| T24 | Ctrl | F | 59 | 2.4 | 12.5 | 5.7 | 34 | 19 | 0.09 | |
| Autoimmune thyroid disorders | T21 | GD | F | 69 |
| 15.7 |
|
|
|
|
| T23 | GD | F | 64 |
|
| 6.3 |
|
|
| |
| T131 | GD | F | 38 |
|
|
|
| 19 |
| |
| T148 | HT | F | 41 | 1.23 | 14.4 | 5.2 |
| 19 | 0.09 |
Ctrl, control; GD, Graves’ disease; HT, Hashimoto’s thyroiditis; TSH, thyroid-stimulating hormone (mU/L, range, 0.5–3.6); FT4, free thyroxin (pmol/L, range, 8–20); FT3, free triiodothyronine (pmol/L, range, 3.5–7.5); TPO-Ab, thyroid peroxidase autoantibodies (IU/mL, ref. < 35); Tg-Ab, thyroglobulin autoantibodies (IU/mL, ref. < 20); TR-Ab, TSH-receptor autoantibodies (IU/L, ref. < 1.8). In bold are values outside normal range.
Partial RNA genome sequences of enterovirus strains obtained from thyroid tissue of patients with autoimmune thyroid disorders.
| Case No. | Representative Sequence | Genome Region | Best Matching EV Species | Identities | Gaps |
|---|---|---|---|---|---|
| T21 | TAATTGGTAGTCCTCCGGCCCCTGAATGCGGCTAATCCTAACTGCGGAGCAGACACCCACGATCCAGTGGGCAGTCTGTCGTAATGGGAAACTCTGCAGCGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTCTTATACTGGCTGCTTATGGTGACAATCA | 5′ UTR | B (echovirus/enterovirus B) | 161/165 | 0 |
| T23 | TGAATGCGGGCAGACACCCACGTCCAGTGGGCAGTCTGTCGTAATGGGAACTCTGCAGCGGAACCGACTACTTTGGTGTACCGTGTTTCA | 5′ UTR | B (echovirus/EV-B) | 83/89 | 5 |
| T131 | TCGTCCGTTCCCACAGTTGCCCGTTACGACTATTCCACATGGTGGCTTCCATGCAATTTTTCTGTGGGGTAGGATTATCCCGCATTCAGGGGCCGGAGGAAG | 5′ UTR | Rhinovirus C | 88/97 | 5 |
| T148 | TAACTGCAGAGCACATGCCCTCAATCCAGGGGGTGGTGTGTCGTAATGGGCAACtCTGCAGCGGAACCGACTACTTTGGTGtCCGTGTTTCAAT | 5′ UTR | A (coxsackievirus A6) | 90/92 | 1 |
Figure 1Green immunofluorescent staining of the enteroviral capsid protein VP1 (MAb 6-E9/2) in the AV3 cell line infected with persistent enterovirus (EV) strains isolated from AITD cases. Red, Evans Blue counterstaining. EV strains from cases T21 (A), T23 (B), T148 (C), T131 (D). Original magnification: 40×, A; 20×, B, C, D.
Figure 2Unsupervised hierarchical clustering of differentially expressed genes. EV-infected cells vs. uninfected cells (left four lanes and right four lanes, respectively). Samples and genes were independently clustered based on the gene expression profile. In the heatmap, red and blue represent high and low expression levels, respectively.
Figure 3Volcano plot. Log2 fold change and −log10 of the adjusted p-value of the differential expression analysis were plotted. The horizontal line represents the adjusted p-value of 0.05. Vertical lines correspond to −0.58 and 0.58 log2 fold changes, which are equivalent to the −1.5 and 1.5 linear fold changes, respectively. Blue dots are differentially expressed genes; red dots are the genes differentially expressed with an absolute value of log2 fold change greater than 0.58.
Gene changes in type I interferon pathways. AV3 cells incubated with enterovirus strains obtained from cases of autoimmune thyroid disorders vs. AV3 cells incubated with a virus-free medium from controls without evidence of thyroid autoimmunity.
| Gene | Gene Function | Log2 Fold Change | Adjusted | Up-/Down- Regulation |
|---|---|---|---|---|
| Type I IFN induction pathway (response to viral RNA) | ||||
| Cytoplasmic sensor of viral nucleic acids. Major role in sensing viral infection and in activating the cascade of antiviral responses including the induction of type I IFNs and proinflammatory cytokines. | −0.19 | 0.436 | - | |
|
| Key component of innate and adaptive immunity, a nucleotide-sensing TLR activated by dsRNA. Acts via the adapter TICAM1. | −0.05 | 0.849 | - |
|
| Component of a multi-helicase–TICAM1 complex acting as a cytoplasmic sensor of viral dsRNA. Activates a cascade of antiviral responses, including proinflammatory cytokines. | −0.18 | 0.144 | - |
|
| Following activation of toll-like receptors by viral or bacterial components, is associated with TRAF3 and TANK and phosphorylates IFN regulatory factors IRF3 and IRF7 and DDX3X. This activity allows subsequent nuclear translocation of IRFs leading to transcriptional activation of type I IFNs and proinflammatory cytokines. Activates IRF3 by phosphorylating innate adapters MAVS, TMEM173/STING, TICAM1, thus leading to recruitment of IRF3. | −0.10 | 0.504 | - |
|
| After binding to viral DNA in the cytoplasm recruits TMEM173/STING and mediates the induction of IFN-beta. Has anti-inflammatory activity and inhibits activation of the AIM2 inflammasome | −0.33 | 0.032 | ↓ |
| Facilitator of innate immune signaling that acts as a sensor of cytosolic DNA from viruses and bacteria and promotes the production of type I IFN. | −0.19 | 0.054 | - | |
|
| IL-1 receptor associated kinase 1 phosphorylates interferon regulatory factor 7 (IRF7) to induce its activation and translocation to the nucleus, resulting in transcriptional activation of type I IFN genes. | −0.26 | 0.010 | ↓ |
|
| Adapter molecule that regulates activation of NFKB and JNK. | −0.29 | 0.144 | - |
|
| Regulates activation of NFKB and JNK. Regulates cell survival and apoptosis. | −0.29 | 0.015 | ↓ |
|
| Regulates pathways leading to the activation of NFKB and MAP kinases. Regulates B cell survival. Part of signaling pathways leading to production of IFN and cytokines. Role in T cell-dependent immune responses. | −0.01 | 0.953 | - |
|
| Activation of NFKB and JNK in response to signaling through TLRs. Regulates cell survival and apoptosis. | −0.25 | 0.017 | ↓ |
|
| Mediates activation of NFKB. | −0.62 | 0.005 | ↓ |
|
| Activation of NFKB and JUN. Role in dendritic cells maturation and/or activation. | −0.22 | 0.022 | ↓ |
| Ikappa kinase (IKK) is an enzyme complex that is part of the NFKB signaling pathway. The IKK complex is comprised of three subunits alpha, beta and gamma. Alpha and beta subunits are catalytically active whereas the gamma subunit has regulatory functions. | −0.53 | 0.002 | ↓ | |
| −0.26 | 0.019 | ↓ | ||
| Noncanonical IKB kinase (IKK) essential for regulating antiviral signaling pathways. | −0.11 | 0.528 | - | |
|
| NFKB is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65–p50 complex. Dimers bind at kappa-B sites in the DNA of target genes and individual dimers have distinct preferences for different kappa-B sites. | 0.39 | 0.004 | ↑ |
|
| NFKB2 has dual functions such as cytoplasmic retention of attached NFKB proteins by p100 and generation of p52 by cotranslational processing. | −0.41 | 0.003 | ↓ |
|
| Member of the NFKB inhibitor family. The protein interacts with REL dimers to inhibit NFKB/REL complexes which are involved in inflammatory responses. | −0.04 | 0.690 | - |
|
| Member of the ankyrin repeat family of proteins known to play a role in inflammatory responses. Activates IL-6 but decreases TNF-alpha production. | −1.16 | <0.001 | ↓ |
|
| The NF-kappa-B heterodimeric RELA–NFKB1 and RELA–REL complexes function as transcriptional activators. The NFKB homodimeric RELA–RELA complex activates IL-8 expression. | 0.46 | 0.040 | ↑ |
|
| NFKB heterodimeric RelB–p50 and RelB–p52 complexes are transcriptional activators. RELB is required for both T and B lymphocyte maturation and function. | 0.18 | 0.171 | - |
|
| Transcriptional regulator serving as an activator of genes involved in antiviral response, including as type I IFNs IFN-alpha/beta, DDX58/RIG-I, TNFSF10/TRAIL, OAS1/2, PIAS1/GBP, EIF2AK2/PKR and RSAD2/viperin. | −0.74 | 0.002 | ↓ |
|
| Key transcriptional regulator of type I IFN-dependent immune responses against viruses. Regulates transcription of type I IFN genes and IFN-stimulated genes by binding to an IFN-stimulated response element (ISRE). | −0.03 | 0.825 | - |
|
| IFN-induced antiviral protein which inhibits the entry of viruses to the cytoplasm permitting endocytosis but preventing subsequent viral fusion and release of viral contents into the cytosol. | −0.44 | 0.007 | ↓ |
| Type I IFN signaling pathway (response to IFN) | ||||
|
| Heterodimer with IFNAR2. Type I IFN binding activates the JAK–STAT signaling cascade and triggers tyrosine phosphorylation of proteins including JAKs, TYK2, STAT and the IFNR alpha- and beta-subunits themselves. | 0.37 | 0.041 | ↑ |
|
| Associates with IFNAR1 to form the type I IFN receptor. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoforms 1 and 2 are involved in signal transduction due to their association with JAK1. | 0.15 | 0.081 | - |
|
| Tyrosine kinase of the non-receptor type involved in the IFN-alpha/beta/gamma signal pathway. | 0.42 | 0.022 | ↑ |
|
| Tyrosine kinase of the non-receptor type involved in different processes (cell growth, differentiation, histone modifications). Mediates signaling events in both innate and adaptive immunity. In the cytoplasm, mediates signal transduction via association with type II receptors (IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins). | −0.32 | 0.036 | ↓ |
|
| Tyrosine kinase that is associated with the cytoplasmic domain of type I and type II cytokine receptors and promulgates cytokine signals by phosphorylating receptor subunits. Component of type I and type III IFN signaling pathways. | −0.41 | 0.006 | ↓ |
|
| TANK binding kinase 1. TBK1 plays a key role in IRF3 activation. First phosphorylates innate adapter proteins MAVS, STING1, TICAM1 leading to recruitment and phosphorylation of IRF3. Phosphorylated IRF3 enters the nucleus to induce expression of interferons. | −0.10 | 0.504 | - |
|
| Transcription activator that mediates cellular responses to IFNs, cytokines, growth factors. Following type I IFN binding to cell receptors, signaling via protein kinases leads to activation of TYK2 and JAK1 and to tyrosine phosphorylation of STAT1 and STAT2. Phosphorylated STATs are associated with ISGF3G/IRF-9, the ISGF3 complex transcription factor that enters the nucleus and promotes transcription of IFN-stimulated genes which drive the cell in an antiviral state. | 0.66 | 0.011 | ↑ |
|
| Signal transducer and activator of transcription that mediates signaling by type I IFNs. | −0.49 | 0.007 | ↓ |
Differentially expressed cytokine-related transcripts. AV3 cells incubated with enterovirus strains obtained from cases of autoimmune thyroid disorders vs. AV3 cells incubated with a virus-free medium from controls without evidence of thyroid autoimmunity.
| Gene | Gene Function | Log2 Fold Change | Adjusted | Up-/Down- Regulation |
|---|---|---|---|---|
|
| Early growth response 1. Transcriptional regulator of cytokines such as IL-1B and CXCL2 that are involved in inflammatory processes. | −1.25 | 0.002 | ↓ |
|
| Chemoattractant active on T lymphocytes and monocytes but not on neutrophils. Activates the C–X–C chemokine receptor CXCR4 to induce an increase in intracellular calcium ions and chemotaxis. | −1.14 | <0.001 | ↓ |
|
| Early growth response gene 2. Regulatory molecule suppressing excessive immune responses. | −0.95 | 0.004 | ↓ |
|
| CCAAT-enhancer-binding-protein beta. Binds to regulatory regions of several acute-phase and cytokine genes and plays a role in the regulation of acute-phase reactions and inflammation. | −0.89 | <0.001 | ↓ |
|
| STAT-induced STAT inhibitor, suppressor of cytokine signaling. The product of this gene is induced by different cytokines and inhibits the JAK2 kinase. | −0.88 | <0.001 | ↓ |
|
| Cytokine of the IL-6 family. Regulates hematopoietic differentiation and neuronal cell differentiation, stimulates synthesis of acute-phase proteins in hepatocytes. | −0.62 | 0.003 | ↓ |
|
| Platelet-derived growth factor beta: regulation of cell proliferation, cell migration, survival and chemotaxis. Inhibitor of inflammatory responses, mitogen for cells of mesenchymal origin. | −0.58 | 0.002 | ↓ |
|
| Functions in inflammation and maturation of B cells. Produced at sites of acute and chronic inflammation. Endogenous pyrogen in autoimmune diseases and infections. Transcriptional inflammatory response through interleukin 6 receptor-alpha. | −0.50 | 0.050 | ↓ |
|
| Related to IL-10, transduces its signal through STAT3. Related pathways are ERK signaling and TGF-beta pathways. | −0.37 | 0.025 | ↓ |
|
| Binds TGF-beta receptors activating the SMAD family transcription factors. The active form consists of a mature peptide homodimer that may form heterodimers with other TGF-beta family members. Regulates cell proliferation, differentiation, growth and expression of other factors including IFN-gamma and TNF-alpha. | −0.36 | 0.005 | ↓ |
|
| Produced by activated macrophages as proprotein that is proteolytically processed to its active form by caspase 1 (CASP1/ICE). It is an important mediator of the inflammatory response and is involved in cell proliferation, differentiation, apoptosis. | −0.34 | 0.007 | ↓ |
|
| Glucose phosphate isomerase protein family. Within the cytoplasm, functions as a glycolytic enzyme that interconverts glucose-6-phosphate and fructose-6-phosphate. Extracellularly, GPI is also referred to as a neuroleukin and functions as a neurotrophic factor and as a lymphokine that induces immunoglobulin secretion. | −0.28 | 0.008 | ↓ |
| Chemotactic activity for myeloid and lymphoid cells, not for neutrophils or eosinophils. Binds to chemokine receptors CCR2 and CCR4. Implicated in diseases characterized by monocytic infiltrates. | 0.23 | 0.049 | ↑ | |
|
| Proinflammatory cytokine; augments NK cell activity in spleen cells, stimulates IFN-gamma production in T helper cells. | 0.31 | 0.032 | ↑ |
Significantly deregulated pathways. AV3 cells incubated with enterovirus strains obtained from cases of autoimmune thyroid disorders vs. AV3 cells incubated with virus-free control supernatants. In bold are significantly deregulated pathways.
| Pathway | Statistical Mean 1 | Number of Genes in the Pathway | |
|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| hsa04380, osteoclast differentiation | 0.82 | 0.051 | 32 |
| hsa04650, natural killer cell-mediated cytotoxicity | 0.80 | 0.058 | 19 |
| hsa04662, B cell receptor signaling pathway | 0.73 | 0.075 | 19 |
| hsa04810, regulation of actin cytoskeleton | 0.71 | 0.082 | 12 |
| hsa04622, RIG-I-like receptor signaling pathway | 0.68 | 0.090 | 20 |
| hsa04370, VEGF signaling pathway | 0.65 | 0.104 | 11 |
1 Quantitative estimate of pathway deregulation.